Selected Start-Ups (2/03)
In Vivo briefly summarizes the technologies of these recently founded companies: Ability Biomedical Corp., Molecular Pathways Inc., NanoGram Devices Corp. NatSpears Ltd. NeuraLieve Inc. and QuantumBio Inc.
You may also be interested in...
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
The EU’s special provisions for speeding new products towards approval proved more popular than ever with drug sponsors last year.
Cardiologists in Europe who have so far been unwilling to embrace the SGLT2 class now have two drugs approved for heart failure with reduced ejection fraction, with Jardiance soon to join Farxiga on the market, potentially attractive options especially for their diabetic patients.